A decrease in NAMPT activity impairs basal PARP-1 activity in cytidine deaminase deficient-cells, independently of NAD
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 08 2020
17 08 2020
Historique:
received:
29
04
2020
accepted:
03
08
2020
entrez:
19
8
2020
pubmed:
19
8
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Cytidine deaminase (CDA) deficiency causes pyrimidine pool disequilibrium. We previously reported that the excess cellular dC and dCTP resulting from CDA deficiency jeopardizes genome stability, decreasing basal poly(ADP-ribose) polymerase 1 (PARP-1) activity and increasing ultrafine anaphase bridge (UFB) formation. Here, we investigated the mechanism underlying the decrease in PARP-1 activity in CDA-deficient cells. PARP-1 activity is dependent on intracellular NAD
Identifiants
pubmed: 32807821
doi: 10.1038/s41598-020-70874-6
pii: 10.1038/s41598-020-70874-6
pmc: PMC7431583
doi:
Substances chimiques
Cytokines
0
NAD
0U46U6E8UK
Niacinamide
25X51I8RD4
Nicotinamide Phosphoribosyltransferase
EC 2.4.2.12
nicotinamide phosphoribosyltransferase, human
EC 2.4.2.12
PARP1 protein, human
EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1
EC 2.4.2.30
Cytidine Deaminase
EC 3.5.4.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13907Références
Veith, S. & Mangerich, A. RecQ helicases and PARP1 team up in maintaining genome integrity. Ageing Res. Rev. 23, 12–28 (2015).
doi: 10.1016/j.arr.2014.12.006
Nygaard, P. On the role of cytidine deaminase in cellular metabolism. In Purine and Pyrimidine Metabolism in Man V: Part B: Basic Science Aspects (eds Nyhan, W. L. et al.) 415–420 (Springer, Boston, 1986).
doi: 10.1007/978-1-4684-1248-2_65
Mameri, H. et al. Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer. Clin. Cancer Res. 23, 2116–2126 (2017).
doi: 10.1158/1078-0432.CCR-16-0626
Ye, F.-G. et al. Cytidine deaminase axis modulated by miR-484 differentially regulates cell proliferation and chemoresistance in breast cancer. Cancer Res. 75, 1504–1515 (2015).
doi: 10.1158/0008-5472.CAN-14-2341
Zauri, M. et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 524, 114 (2015).
doi: 10.1038/nature14948
Bou Samra, E. et al. A role for Tau protein in maintaining ribosomal DNA stability and cytidine deaminase-deficient cell survival. Nat. Commun. 8, 693 (2017).
doi: 10.1038/s41467-017-00633-1
Chabosseau, P. et al. Pyrimidine pool imbalance induced by BLM helicase deficiency contributes to genetic instability in Bloom syndrome. Nat. Commun. 2, 368 (2011).
doi: 10.1038/ncomms1363
Gemble, S. et al. A balanced pyrimidine pool is required for optimal Chk1 activation to prevent ultrafine anaphase bridge formation. J. Cell Sci. 129, 3167–3177 (2016).
doi: 10.1242/jcs.187781
Gemble, S., Buhagiar-Labarchède, G., Onclercq-Delic, R., Jaulin, C. & Amor-Guéret, M. Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity. Cell Cycle 16, 1128–1135 (2017).
doi: 10.1080/15384101.2017.1317413
Gemble, S. et al. Pyrimidine pool disequilibrium induced by a cytidine deaminase deficiency inhibits PARP-1 activity, leading to the under replication of DNA. PLoS Genet. 11, e1005384 (2015).
doi: 10.1371/journal.pgen.1005384
Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610 (2017).
doi: 10.1038/nrm.2017.53
Revollo, J. R., Grimm, A. A. & Imai, S.-I. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279, 50754–50763 (2004).
doi: 10.1074/jbc.M408388200
Yaku, K. et al. Metabolism and biochemical properties of nicotinamide adenine dinucleotide (NAD) analogs, nicotinamide guanine dinucleotide (NGD) and nicotinamide hypoxanthine dinucleotide (NHD). Sci. Rep. 9, 13102 (2019).
doi: 10.1038/s41598-019-49547-6
Garten, A., Petzold, S., Körner, A., Imai, S.-I. & Kiess, W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130–138 (2009).
doi: 10.1016/j.tem.2008.10.004
Sommer, G. et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin. Sci. 115, 13–23 (2008).
doi: 10.1042/CS20070226
Garten, A. et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat. Rev. Endocrinol. 11, 535 (2015).
doi: 10.1038/nrendo.2015.117
Baumann, C., Körner, R., Hofmann, K. & Nigg, E. A. PICH, a Centromere-associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint. Cell 128, 101–114 (2007).
doi: 10.1016/j.cell.2006.11.041
Buonvicino, D. et al. Identification of the nicotinamide salvage pathway as a new toxification route for antimetabolites. Cell Chem. Biol. 25, 471-482.e477 (2018).
doi: 10.1016/j.chembiol.2018.01.012
Piacente, F. et al. Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair. Cancer Res. 77, 3857–3869 (2017).
doi: 10.1158/0008-5472.CAN-16-3079
Wang, T. et al. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol. 13, 661 (2006).
doi: 10.1038/nsmb1114
Bockwoldt, M. et al. Identification of evolutionary and kinetic drivers of NAD-dependent signaling. Proc. Natl. Acad. Sci. 116, 15957–15966 (2019).
doi: 10.1073/pnas.1902346116
Pissios, P. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme. Trends Endocrinol. Metab. 28, 340–353 (2017).
doi: 10.1016/j.tem.2017.02.004
Guo, J. et al. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation. Biochem. Biophys. Res. Commun. 491, 681–686 (2017).
doi: 10.1016/j.bbrc.2017.07.143
Bajrami, I. et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol. Med. 4, 1087–1096 (2012).
doi: 10.1002/emmm.201201250
Heske, C. M. et al. Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing Sarcoma. Clin. Cancer Res. 23, 7301–7311 (2017).
doi: 10.1158/1078-0432.CCR-17-1121
Heske, C. M. Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy. Front. Oncol. 9, 1514 (2020).
doi: 10.3389/fonc.2019.01514
Rouzeau, S. et al. Bloom’s syndrome and PICH helicases cooperate with topoisomerase IIalpha in centromere disjunction before anaphase. PLoS ONE 7, e33905 (2012).
doi: 10.1371/journal.pone.0033905
Elliott, G. C., Ajioka, J. & Okada, C. Y. A rapid procedure for assaying nicotinamide phosphoribosyltransferase. Anal. Biochem. 107, 199–205 (1980).
doi: 10.1016/0003-2697(80)90512-6